Product combination for the treatment of filovirus infections

The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. Although several antivirals have shown efficacy against Ebola virus infection in vitro or in animal models, few of them have been yet assessed in human beings with Ebola virus disease. The inventors aimed at identifying novel antivirals showing efficacy against Ebola virus infection. Gemcitabine and obatoclax were identified and their synergistic effects with favipiravir were demonstrated. In particular, the present invention relates to a method of treating a filovirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective combination of favipiravir and Obatoclax. The present invention also relates to a method of treating a filovirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective combination of favipiravir and gemcitabine.

Keywords: Infectious diseases, antivirals, virus, Ebola,
Patent Application number: European Procedure (Patents) (EPA) - 23 Mai 2016 - 16 305 590.8

Reference:

BIO16121-T1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 23-05-2016
Rare disease: No
Second indication: No

You might also be interested in